These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 12071124)

  • 1. [Reducing postprandial glucose levels. Glucosidase antagonists].
    Neye H
    Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
    [No Abstract]   [Full Text] [Related]  

  • 2. Miglitol and hepatotoxicity in type 2 diabetes mellitus.
    Carlson RF
    Am Fam Physician; 2000 Jul; 62(2):315, 318. PubMed ID: 10929699
    [No Abstract]   [Full Text] [Related]  

  • 3. [Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor].
    MMW Fortschr Med; 2000 Jul; 142(26-27):54-5. PubMed ID: 10929491
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
    Sakamoto N; Tajima N
    Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug therapy of type 2 diabetes: insulin sensitizers improve results].
    Stadler HJ
    Pflege Z; 1999 Nov; 52(11):772-5. PubMed ID: 10788929
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving management of type 2 diabetes mellitus: 1. alpha-Glucosidase inhibitors.
    Kuritzky L; Samraj G; Quillen DM
    Hosp Pract (1995); 1999 Sep; 34(10):43-6. PubMed ID: 10901748
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents.
    Scheen AJ; Lefèbvre PJ
    Diabetes Care; 2002 Jan; 25(1):247-8. PubMed ID: 11772929
    [No Abstract]   [Full Text] [Related]  

  • 8. Type 2 diabetes: glycemic targets and oral therapies for older patients.
    Lardinois CK
    Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
    Fehmann HC
    MMW Fortschr Med; 2000 May; 142(21):55. PubMed ID: 10872296
    [No Abstract]   [Full Text] [Related]  

  • 10. Miglitol for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1999 May; 41(1053):49-50. PubMed ID: 10368700
    [No Abstract]   [Full Text] [Related]  

  • 11. alpha-Glucosidase inhibition in the treatment of diabetes mellitus.
    Dimitriadis G; Raptis S
    Horm Metab Res Suppl; 1992; 26():42-9. PubMed ID: 1490691
    [No Abstract]   [Full Text] [Related]  

  • 12. [Inhibitors of alpha-glucosidase].
    Toeller M
    Journ Annu Diabetol Hotel Dieu; 1991; ():203-12. PubMed ID: 1886331
    [No Abstract]   [Full Text] [Related]  

  • 13. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus.
    Scott LJ; Spencer CM
    Drugs; 2000 Mar; 59(3):521-49. PubMed ID: 10776834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetic, pharmacological, and clinical profile of miglitol (SEIBULE), a novel alpha-glucosidase inhibitor].
    Kuboyama N; Hayashi I; Yamaguchi T
    Nihon Yakurigaku Zasshi; 2006 Mar; 127(3):223-32. PubMed ID: 16651808
    [No Abstract]   [Full Text] [Related]  

  • 15. Miglitol, a new alpha-glucosidase inhibitor.
    Sels JP; Huijberts MS; Wolffenbuttel BH
    Expert Opin Pharmacother; 1999 Nov; 1(1):149-56. PubMed ID: 11249557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current status of the treatment of type 2 diabetes mellitus. Alpha-glucosidase inhibitors].
    Blicklé JF; Andres E; Brogard JM
    Rev Med Interne; 1999 Aug; 20 Suppl 3():379s-383s. PubMed ID: 10480189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
    Kellerer M; Jakob S; Linn T; Haslbeck M
    MMW Fortschr Med; 2003 Dec; 145(51-52):I-X; quiz XI-XII. PubMed ID: 14974337
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of alpha-inhibitors on blood glucose and insulin levels.
    Laube H; Federlin K; Hillebrand I
    Adv Exp Med Biol; 1988; 246():287-93. PubMed ID: 3074658
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
    Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
    Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.